Skip to NavigationSkip to content

axial spondyloarthritis

EU approval for Novartis' Cosentyx in active non-radiographic axial spondyloarthritis

Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients.

The authorisation was awarded after Phase 3 data drawn from the largest-ever study of a biologic drug in nr-axSpA showed that Cosentyx met its primary endpoint in trials investigating its efficacy in treating the condition.

An estimated 1.7 million patients live with nr-axSpA across the US and the top five EU countries.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches